HomeInsightsStock Comparison

Aurobindo Pharma Ltd vs Granules India Ltd Stock Comparison

Aurobindo Pharma Ltd vs Granules India Ltd Stock Comparison

Last Updated on: Jun 26, 2025

Key Highlights

  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1132 as of 26 Jun 09:19.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 yearsThe P/E Ratio of Granules India Ltd changed from 10.9 on March 2020 to 25.7 on March 2024 . This represents a CAGR of 18.71% over 5 years.
  • The Market Cap of Aurobindo Pharma Ltd changed from ₹ 24202 crore on March 2020 to ₹ 63835 crore on March 2024 . This represents a CAGR of 21.41% over 5 yearsThe Market Cap of Granules India Ltd changed from ₹ 3650 crore on March 2020 to ₹ 10420 crore on March 2024 . This represents a CAGR of 23.34% over 5 years.
  • The revenue of Aurobindo Pharma Ltd for the Mar '25 is ₹ 8516 crore as compare to the Dec '24 revenue of ₹ 8137 crore. This represent the growth of 4.66% The revenue of Granules India Ltd for the Mar '25 is ₹ 1230 crore as compare to the Dec '24 revenue of ₹ 1143 crore. This represent the growth of 7.59%.
  • The ebitda of Aurobindo Pharma Ltd for the Mar '25 is ₹ 1894 crore as compare to the Dec '24 ebitda of ₹ 1736 crore. This represent the growth of 9.08% The ebitda of Granules India Ltd for the Mar '25 is ₹ 285.03 crore as compare to the Dec '24 ebitda of ₹ 235.97 crore. This represent the growth of 20.79%.
  • The net profit of Aurobindo Pharma Ltd changed from ₹ 569.71 crore to ₹ 902.83 crore over 8 quarters. This represents a CAGR of 25.89% The net profit of Granules India Ltd changed from ₹ 47.9 crore to ₹ 152.03 crore over 8 quarters. This represents a CAGR of 78.15% .
  • The Dividend Payout of Aurobindo Pharma Ltd changed from 9.37 % on March 2020 to 13.49 % on March 2024 . This represents a CAGR of 7.56% over 5 yearsThe Dividend Payout of Granules India Ltd changed from 5.72 % on March 2020 to 8.34 % on March 2024 . This represents a CAGR of 7.83% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Granules India Ltd

  • Granules India Limited is a large-scale vertically integrated company founded in March 18th, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
  • With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
  • The company has a global presence across over 80 countries servicing over 300 customers.
  • Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies.
  • The company has one of largest PFI and single site FD facilities in the world.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma gets UK MHRA approval for neutropenia treatment drug Dyrupeg

Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a ...

Read more

25 Jun 2025 12:51

News

CuraTeQ Biologics receives UK MHRA approval for biosimilar Dyrupeg'

Aurobindo Pharma announced that CuraTeQ Biologics s.r.o., a wholly owned step-down subsidi...

Read more

24 Jun 2025 19:01

News

Aurobindo Pharma Ltd down for fifth straight session

Aurobindo Pharma Ltd is down for a fifth straight session today. The stock is quoting at R...

Read more

17 Jun 2025 13:35

News

Aurobindo Pharma's US arm incorporates Cresedemo Pharma

The purpose of incorporating this new entity is to expand the company's pharmaceutical pro...

Read more

16 Jun 2025 08:40

News

Aurobindo Pharma incorporates WoS in USA

Aurobindo Pharma USA Inc. has incorporated a new wholly owned subsidiary in USA by the nam...

Read more

16 Jun 2025 10:34

News

Aurobindo Pharma arm incorporates WOS in Netherlands

The purpose of the incorporation of this wholly owned subsidiary is to expand the biopharm...

Read more

29 May 2025 08:40

Granules India Ltd News Hub

News

Granules India receives one observation from USFDA following inspection at Telangana facility

In a regulatory filing, the company stated that the USFDA conducted the inspection from 16...

Read more

23 Jun 2025 09:36

News

Granules India allots Equity shares

Granules India has approved the allotment of 1,00,000 equity shares in consequence of the ...

Read more

17 Jun 2025 11:30

News

Granules India announces cessation of Vice President & Head- IT

Granules India announced that Krishnamohan B., shall to be the Senior Management Personnel...

Read more

02 Jun 2025 12:46

News

Granules India to convene AGM

Granules India announced that the 34th Annual General Meeting(AGM) of the company will be ...

Read more

28 May 2025 14:10

News

Board of Granules India recommends final dividend

Granules India announced that the Board of Directors of the Company at its meeting held on...

Read more

28 May 2025 14:11

News

Granules India to declare Quarterly Result

Granules India will hold a meeting of the Board of Directors of the Company on 28 May 2025...

Read more

07 May 2025 11:42

SWOT Analysis Of Granules India Ltd

Strength

4

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Granules India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aurobindo Pharma Ltd and Granules India Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Granules India Ltd?

Market cap of Aurobindo Pharma Ltd is 65,630 Cr while Market cap of Granules India Ltd is 11,987 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Granules India Ltd?

The stock performance of Aurobindo Pharma Ltd and Granules India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Granules India Ltd?

As of June 26, 2025, the Aurobindo Pharma Ltd stock price is INR ₹1120.1. On the other hand, Granules India Ltd stock price is INR ₹494.05.

How do dividend payouts of Aurobindo Pharma Ltd and Granules India Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Granules India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions